<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25580775</article-id><article-id pub-id-type="pmc">5024060</article-id><article-id pub-id-type="doi">10.1111/dom.12435</article-id><article-id pub-id-type="publisher-id">DOM12435</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letters</subject></subj-group></article-categories><title-group><article-title>Lobeglitazone and pioglitazone as add&#x02010;ons to metformin for patients with type 2 diabetes: a 24&#x02010;week, multicentre, randomized, double&#x02010;blind, parallel&#x02010;group, active&#x02010;controlled, phase <styled-content style="fixed-case">III</styled-content> clinical trial with a 28&#x02010;week extension</article-title><alt-title alt-title-type="left-running-head">Jin et al.</alt-title></title-group><contrib-group><contrib id="dom12435-cr-0001" contrib-type="author"><name><surname>Jin</surname><given-names>S.&#x02010;M.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="dom12435-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="dom12435-cr-0002" contrib-type="author"><name><surname>Park</surname><given-names>C.&#x02010;Y.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="dom12435-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="dom12435-cr-0003" contrib-type="author"><name><surname>Cho</surname><given-names>Y. M.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12435-cr-0004" contrib-type="author"><name><surname>Ku</surname><given-names>B. J.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12435-cr-0005" contrib-type="author"><name><surname>Ahn</surname><given-names>C. W.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12435-cr-0006" contrib-type="author"><name><surname>Cha</surname><given-names>B.&#x02010;S.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12435-cr-0007" contrib-type="author"><name><surname>Min</surname><given-names>K. W.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom12435-cr-0008" contrib-type="author"><name><surname>Sung</surname><given-names>Y. A.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="dom12435-cr-0009" contrib-type="author"><name><surname>Baik</surname><given-names>S. H.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="dom12435-cr-0010" contrib-type="author"><name><surname>Lee</surname><given-names>K. W.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="dom12435-cr-0011" contrib-type="author"><name><surname>Yoon</surname><given-names>K.&#x02010;H.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="dom12435-cr-0012" contrib-type="author"><name><surname>Lee</surname><given-names>M.&#x02010;K.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12435-cr-0013" contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>S. W.</given-names></name><xref ref-type="aff" rid="dom12435-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="dom12435-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Metabolism, Department of Medicine</named-content><institution>Samsung Medical Centre, Sungkyunkwan University School of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Endocrinology and Metabolism</named-content><institution>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Seoul National University College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>School of Medicine, Chungnam National University</institution><named-content content-type="city">Daejeon</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Gangnam Severance Hospital, Yonsei University of College of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Severance Hospital, Yonsei University of Collage of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0007"><label><sup>7</sup></label><institution>Diabetes Centre, Department of Endocrinology and Metabolism, Eulji General Hospital, Eulji University School of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>EwhaWomans University School of Medicine</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Metabolism, Department of Internal Medicine</named-content><institution>College of Medicine, Korea University</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0010"><label><sup>10</sup></label><named-content content-type="organisation-division">Department of Endocrinology and Metabolism</named-content><institution>Ajou University School of Medicine</institution><named-content content-type="city">Suwon</named-content><country country="KR">Republic of Korea</country></aff><aff id="dom12435-aff-0011"><label><sup>11</sup></label><named-content content-type="organisation-division">Department of Endocrinology and Metabolism, Immunology, Cell Biology Core Laboratory</named-content><institution>Institutes of Medical Science, The Catholic University of Korea</institution><named-content content-type="city">Seoul</named-content><country country="KR">Republic of Korea</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Sung Woo Park, MD, PhD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, 29, Saemunan&#x02010;ro, Jongno&#x02010;gu, Seoul 110&#x02010;746, Republic of Korea.<break/>
E&#x02010;mail: <email>sungwoo0913.park@samsung.com</email><break/></corresp><fn id="dom12435-note-0001"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>08</day><month>2</month><year>2015</year></pub-date><volume>17</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/dom.2015.17.issue-6</issue-id><fpage>599</fpage><lpage>602</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>06</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2014</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-17-599.pdf"/><abstract id="dom12435-abs-0001"><p id="dom12435-para-0001">We aimed to compare the efficacy and safety of lobeglitazone and pioglitazone as add&#x02010;ons to metformin in patients with type 2 diabetes. Patients who were inadequately controlled by metformin were randomized and treated once daily with either lobeglitazone (0.5&#x02009;mg, n&#x02009;=&#x02009;128) or pioglitazone (15&#x02009;mg, n&#x02009;=&#x02009;125) for 24&#x02009;weeks, with a 28&#x02010;week extension trial of lobeglitazone treatment in patients who consented. The primary endpoint was the change in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) concentration from baseline to week&#x02009;24. At week&#x02009;24, the mean change from baseline in <styled-content style="fixed-case">HbA1c</styled-content> was &#x02212;0.74% for the lobeglitazone group and &#x02212;0.74% for the pioglitazone group, with a mean difference of 0.01% [95% confidence interval (<styled-content style="fixed-case">CI</styled-content>) of difference, &#x02212;0.16 to 0.18]. The effects of lobeglitazone on lipid variables and the adverse events associated with lobeglitazone were similar to those observed with pioglitazone. Lobeglitazone was not inferior to pioglitazone as an add&#x02010;on to metformin in terms of their efficacy and safety.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12435-kwd-0001">antidiabetic drug</kwd><kwd id="dom12435-kwd-0002">clinical trial</kwd><kwd id="dom12435-kwd-0003">phase <styled-content style="fixed-case">III</styled-content> study</kwd><kwd id="dom12435-kwd-0004">randomised trial</kwd><kwd id="dom12435-kwd-0005">thiazolidinediones</kwd></kwd-group><funding-group><award-group><funding-source>Chong Kun Dang Pharmaceutical Corp.</funding-source></award-group></funding-group><counts><page-count count="4"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12435</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:15.09.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12435-sec-0001"><title>Introduction</title><p id="dom12435-para-0002">Despite the continuing debate about the safety of thiazolidinedione (TZD) <xref rid="dom12435-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12435-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12435-bib-0003" ref-type="ref">3</xref> and attempts to develop new classes of insulin sensitizers <xref rid="dom12435-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12435-bib-0005" ref-type="ref">5</xref>, there is still a clinical need for a novel TZD. Lobeglitazone (CKD&#x02010;501; Chong Kun Dang Pharmaceutical Corp., Seoul, Korea) is a novel peroxisome proliferator&#x02010;activated receptor (PPAR)&#x02010;&#x003b3; agonist with a TZD moiety and substituted pyrimidines <xref rid="dom12435-bib-0006" ref-type="ref">6</xref>. These substituted pyrimidines were selected on their empirical effects on triglyceride accumulation in adipocytes <italic>in vitro</italic> and their glucose&#x02010;lowering and lipid&#x02010;modulating activities in diabetic mice <italic>in vivo</italic>
<xref rid="dom12435-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12435-bib-0008" ref-type="ref">8</xref>. Unlike pioglitazone, urinary excretion of lobeglitazone is negligible in humans <xref rid="dom12435-bib-0009" ref-type="ref">9</xref>; moreover, no bladder cancer has been observed in 2&#x02010;year carcinogenicity studies in mice <xref rid="dom12435-bib-0010" ref-type="ref">10</xref> and rats <xref rid="dom12435-bib-0011" ref-type="ref">11</xref>. In pharmacokinetic studies in healthy adults, lobeglitazone was well&#x02010;tolerated and did not significantly affect the pharmacokinetics of metformin or <italic>vice versa</italic>
<xref rid="dom12435-bib-0012" ref-type="ref">12</xref>. The aim of the present study was therefore to compare the efficacy and safety of lobeglitazone and pioglitazone as add&#x02010;ons to metformin for patients with type 2 diabetes.</p></sec><sec id="dom12435-sec-0002"><title>Patients and Methods</title><p id="dom12435-para-0003">This was a 24&#x02010;week, randomized, double&#x02010;blind, parallel&#x02010;group, active&#x02010;controlled, phase III clinical trial conducted from June 2010 to April 2012 in 18 centres in the Republic of Korea. Patients were recruited by the investigators from the outpatient clinic of each centre. Advertisements in newspapers and subways were used to facilitate patient recruitment. An additional 28&#x02010;week extension phase of lobeglitazone treatment was conducted for patients who consented to further assessment of safety profiles. The clinical trial protocol was approved by the institutional review board of each centre. This trial complied with the Declaration of Helsinki and is registered with <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT01106131). All patients in the present study provided written informed consent.</p><p id="dom12435-para-0004">Patients aged 18&#x02013;80&#x02009;years (body mass index 21&#x02013;40&#x02009;kg/m<sup>2</sup>) with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) concentration 7&#x02013;10% (53&#x02013;86&#x02009;mmol/mol)], and a fasting C&#x02010;peptide concentration&#x02009;&#x0003e;1.0&#x02009;ng/ml, despite a stable regimen of metformin (&#x02265;1000&#x02009;mg/day; unchanged for at least 2&#x02009;months before randomization) were eligible for this study. The exclusion criteria for this study are available in File S1.</p><p id="dom12435-para-0005">After a 2&#x02010;week, single&#x02010;blind, placebo run&#x02010;in period, eligible patients were randomized (1&#x02009;:&#x02009;1) to receive once&#x02010;daily lobeglitazone (0.5&#x02009;mg) plus pioglitazone placebo or once&#x02010;daily pioglitazone (15&#x02009;mg) plus lobeglitazone placebo as an add&#x02010;on therapy to metformin (&#x02265;1000&#x02009;mg/day) for 24&#x02009;weeks. The primary endpoint was the change in HbA1c concentration between baseline and week&#x02009;24. This trial was designed as a non&#x02010;inferiority trial to establish whether lobeglitazone was not inferior to pioglitazone in terms of the primary endpoint. The 95% lower confidence limit for the between&#x02010;treatment difference was estimated and compared with the predefined &#x02212;0.4% non&#x02010;inferiority margin. Details of the study protocol and statistical methods are available in File S1.</p></sec><sec id="dom12435-sec-0003"><title>Results</title><sec id="dom12435-sec-0004"><title>Baseline Characteristics</title><p id="dom12435-para-0006">A total of 253 patients were randomized and comprised the full analysis set. Of these patients, 128 were treated with lobeglitazone and 125 were treated with pioglitazone. Overall, 222 patients (87.7%) completed the treatment period (Figure S1, File S1). The baseline characteristics did not differ between the two groups (Table S1, File S1). No initial differences were observed between the groups regarding the distribution of co&#x02010;administered drugs, liver function test results, bone densitometry scans, or N&#x02010;terminal pro&#x02010;brain natriuretic peptide levels (data not shown). Three patients in the pioglitazone group were given increased doses of pioglitazone as a result of hyperglycaemia [HbA1c &#x0003e;8.0% (64&#x02009;mmol/mol), fasting plasma glucose &#x0003e;11.1&#x02009;mmol/L] at week&#x02009;12.</p></sec><sec id="dom12435-sec-0005"><title>Primary and Secondary Efficacy Endpoints</title><p id="dom12435-para-0007">The reduction in HbA1c concentration between baseline and week&#x02009;24 was 0.74% in the lobeglitazone group and 0.74% in the pioglitazone group (Figure <xref rid="dom12435-fig-0001" ref-type="fig">1</xref>). The mean difference between these groups was 0.01% [95% confidence interval (CI) of difference, &#x02212;0.16 to 0.18]. The change in HbA1c level from baseline was significant in both groups (p&#x02009;&#x0003c;&#x02009;0.001). The proportion of patients who achieved an HbA1c concentration of &#x0003c;7.0% was 47.7% for the lobeglitazone group and 48.0% for the pioglitazone group (p&#x02009;<italic>=</italic>&#x02009;0.956).</p><fig fig-type="Figure" xml:lang="en" id="dom12435-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean changes in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) and lipid variables from baseline (lobeglitazone group, n&#x02009;=&#x02009;128; pioglitazone group, n&#x02009;=&#x02009;125). For the extension study, the results obtained for the 83 patients who continued lobeglitazone (lobeglitazone group) and the 94 patients who switched to lobeglitazone from pioglitazone (pioglitazone group) are shown.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-17-599-g001"><alt-text>DOM-12435-FIG-0001-b</alt-text></graphic></fig><p id="dom12435-para-0008">Significant decreases in fasting plasma glucose, homeostatic model assessment of insulin resistance, fasting insulin and fasting C&#x02010;peptide levels, in addition to increases in homeostatic model assessment of &#x003b2;&#x02010;cell function, were observed in both groups; no differences were observed between the two groups (Table <xref rid="dom12435-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12435-fig-0001" ref-type="fig">1</xref>; Figure S2, File S1). Significant increases in HDL cholesterol and adiponectin levels, in addition to decreases in free fatty acid and triglyceride levels, were observed in both groups. The changes in LDL cholesterol levels were similar in each group (Table <xref rid="dom12435-tbl-0001" ref-type="table-wrap">1</xref> and Figure <xref rid="dom12435-fig-0001" ref-type="fig">1</xref>).</p><table-wrap id="dom12435-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Effects of lobeglitazone versus pioglitazone on glucometabolic and lipid variables between baseline and 24&#x02009;weeks</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" id="dom12435-ent-0001" align="left" valign="bottom" colspan="1">Variable</th><th colspan="2" align="left" id="dom12435-ent-0002" valign="bottom" rowspan="1">Lobeglitazone (n&#x02009;=&#x02009;128)</th><th colspan="2" align="left" id="dom12435-ent-0003" valign="bottom" rowspan="1">Pioglitazone (n&#x02009;=&#x02009;125)</th><th rowspan="2" id="dom12435-ent-0004" align="left" valign="bottom" colspan="1">p<xref ref-type="fn" rid="dom12435-note-0005">*</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12435-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th id="dom12435-ent-0006" align="left" valign="bottom" rowspan="1" colspan="1">Week 24</th><th id="dom12435-ent-0007" align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th id="dom12435-ent-0008" align="left" valign="bottom" rowspan="1" colspan="1">Week 24</th></tr></thead><tbody valign="top"><tr><td rowspan="2" id="dom12435-ent-0009" align="left" valign="top" colspan="1">HbA1c, % (mmol/mol)</td><td id="dom12435-ent-0010" align="left" valign="top" rowspan="1" colspan="1">7.93&#x02009;&#x000b1;&#x02009;0.75</td><td id="dom12435-ent-0011" align="left" valign="top" rowspan="1" colspan="1">7.19&#x02009;&#x000b1;&#x02009;0.86<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0012" align="left" valign="top" rowspan="1" colspan="1">7.96&#x02009;&#x000b1;&#x02009;0.70</td><td id="dom12435-ent-0013" align="left" valign="top" rowspan="1" colspan="1">7.22&#x02009;&#x000b1;&#x02009;0.83<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td rowspan="2" id="dom12435-ent-0014" align="left" valign="top" colspan="1">0.858</td></tr><tr><td id="dom12435-ent-0015" align="left" valign="top" rowspan="1" colspan="1">(63&#x02009;&#x000b1;&#x02009;8)</td><td id="dom12435-ent-0016" align="left" valign="top" rowspan="1" colspan="1">(55&#x02009;&#x000b1;&#x02009;9)</td><td id="dom12435-ent-0017" align="left" valign="top" rowspan="1" colspan="1">(63&#x02009;&#x000b1;&#x02009;8)</td><td id="dom12435-ent-0018" align="left" valign="top" rowspan="1" colspan="1">(55&#x02009;&#x000b1;&#x02009;9)</td></tr><tr><td id="dom12435-ent-0019" align="left" valign="top" rowspan="1" colspan="1">Fasting glucose, mmol/l</td><td id="dom12435-ent-0020" align="left" valign="top" rowspan="1" colspan="1">8.57&#x02009;&#x000b1;&#x02009;2.61</td><td id="dom12435-ent-0021" align="left" valign="top" rowspan="1" colspan="1">7.31&#x02009;&#x000b1;&#x02009;2.22<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0022" align="left" valign="top" rowspan="1" colspan="1">8.67&#x02009;&#x000b1;&#x02009;2.17</td><td id="dom12435-ent-0023" align="left" valign="top" rowspan="1" colspan="1">7.20&#x02009;&#x000b1;&#x02009;1.60<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0024" align="left" valign="top" rowspan="1" colspan="1">0.433</td></tr><tr><td id="dom12435-ent-0025" align="left" valign="top" rowspan="1" colspan="1">Fasting insulin, pmol/l</td><td id="dom12435-ent-0026" align="left" valign="top" rowspan="1" colspan="1">67.85&#x02009;&#x000b1;&#x02009;41.18</td><td id="dom12435-ent-0027" align="left" valign="top" rowspan="1" colspan="1">57.85&#x02009;&#x000b1;&#x02009;26.18<xref ref-type="fn" rid="dom12435-note-2004">
<sup>&#x02021;</sup>
</xref>
</td><td id="dom12435-ent-0028" align="left" valign="top" rowspan="1" colspan="1">67.37&#x02009;&#x000b1;&#x02009;36.46</td><td id="dom12435-ent-0029" align="left" valign="top" rowspan="1" colspan="1">54.45&#x02009;&#x000b1;&#x02009;24.17<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0030" align="left" valign="top" rowspan="1" colspan="1">0.232</td></tr><tr><td id="dom12435-ent-0031" align="left" valign="top" rowspan="1" colspan="1">Fasting C&#x02010;peptide, nmol/l</td><td id="dom12435-ent-0032" align="left" valign="top" rowspan="1" colspan="1">0.76&#x02009;&#x000b1;&#x02009;0.36</td><td id="dom12435-ent-0033" align="left" valign="top" rowspan="1" colspan="1">0.67&#x02009;&#x000b1;&#x02009;0.25<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0034" align="left" valign="top" rowspan="1" colspan="1">0.77&#x02009;&#x000b1;&#x02009;0.37</td><td id="dom12435-ent-0035" align="left" valign="top" rowspan="1" colspan="1">0.65&#x02009;&#x000b1;&#x02009;0.28<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0036" align="left" valign="top" rowspan="1" colspan="1">0.502</td></tr><tr><td id="dom12435-ent-0037" align="left" valign="top" rowspan="1" colspan="1">HOMA&#x02010;&#x003b2;</td><td id="dom12435-ent-0038" align="left" valign="top" rowspan="1" colspan="1">44.24&#x02009;&#x000b1;&#x02009;26.49</td><td id="dom12435-ent-0039" align="left" valign="top" rowspan="1" colspan="1">52.02&#x02009;&#x000b1;&#x02009;34.88<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0040" align="left" valign="top" rowspan="1" colspan="1">42.83&#x02009;&#x000b1;&#x02009;28.02</td><td id="dom12435-ent-0041" align="left" valign="top" rowspan="1" colspan="1">51.08&#x02009;&#x000b1;&#x02009;45.01<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0042" align="left" valign="top" rowspan="1" colspan="1">0.916</td></tr><tr><td id="dom12435-ent-0043" align="left" valign="top" rowspan="1" colspan="1">HOMA&#x02010;IR</td><td id="dom12435-ent-0044" align="left" valign="top" rowspan="1" colspan="1">3.89&#x02009;&#x000b1;&#x02009;3.69</td><td id="dom12435-ent-0045" align="left" valign="top" rowspan="1" colspan="1">2.69&#x02009;&#x000b1;&#x02009;1.29<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0046" align="left" valign="top" rowspan="1" colspan="1">3.79&#x02009;&#x000b1;&#x02009;2.62</td><td id="dom12435-ent-0047" align="left" valign="top" rowspan="1" colspan="1">2.54&#x02009;&#x000b1;&#x02009;1.36<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0048" align="left" valign="top" rowspan="1" colspan="1">0.358</td></tr><tr><td id="dom12435-ent-0049" align="left" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/l</td><td id="dom12435-ent-0050" align="left" valign="top" rowspan="1" colspan="1">4.19&#x02009;&#x000b1;&#x02009;0.90</td><td id="dom12435-ent-0051" align="left" valign="top" rowspan="1" colspan="1">4.37&#x02009;&#x000b1;&#x02009;0.90<xref ref-type="fn" rid="dom12435-note-2004">
<sup>&#x02021;</sup>
</xref>
</td><td id="dom12435-ent-0052" align="left" valign="top" rowspan="1" colspan="1">4.39&#x02009;&#x000b1;&#x02009;0.99</td><td id="dom12435-ent-0053" align="left" valign="top" rowspan="1" colspan="1">4.58&#x02009;&#x000b1;&#x02009;0.91<xref ref-type="fn" rid="dom12435-note-2004">
<sup>&#x02021;</sup>
</xref>
</td><td id="dom12435-ent-0054" align="left" valign="top" rowspan="1" colspan="1">0.410</td></tr><tr><td id="dom12435-ent-0055" align="left" valign="top" rowspan="1" colspan="1">Triglyceride, mmol/l</td><td id="dom12435-ent-0056" align="left" valign="top" rowspan="1" colspan="1">1.58&#x02009;&#x000b1;&#x02009;0.77</td><td id="dom12435-ent-0057" align="left" valign="top" rowspan="1" colspan="1">1.44&#x02009;&#x000b1;&#x02009;0.65<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0058" align="left" valign="top" rowspan="1" colspan="1">1.77&#x02009;&#x000b1;&#x02009;1.25</td><td id="dom12435-ent-0059" align="left" valign="top" rowspan="1" colspan="1">1.55&#x02009;&#x000b1;&#x02009;0.98<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0060" align="left" valign="top" rowspan="1" colspan="1">0.783</td></tr><tr><td id="dom12435-ent-0061" align="left" valign="top" rowspan="1" colspan="1">LDL cholesterol, mmol/l</td><td id="dom12435-ent-0062" align="left" valign="top" rowspan="1" colspan="1">2.29&#x02009;&#x000b1;&#x02009;0.82</td><td id="dom12435-ent-0063" align="left" valign="top" rowspan="1" colspan="1">2.41&#x02009;&#x000b1;&#x02009;0.81<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0064" align="left" valign="top" rowspan="1" colspan="1">2.46&#x02009;&#x000b1;&#x02009;0.82</td><td id="dom12435-ent-0065" align="left" valign="top" rowspan="1" colspan="1">2.58&#x02009;&#x000b1;&#x02009;0.85<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0066" align="left" valign="top" rowspan="1" colspan="1">0.530</td></tr><tr><td id="dom12435-ent-0067" align="left" valign="top" rowspan="1" colspan="1">Small dense LDL cholesterol (%)</td><td id="dom12435-ent-0068" align="left" valign="top" rowspan="1" colspan="1">4.02&#x02009;&#x000b1;&#x02009;4.68</td><td id="dom12435-ent-0069" align="left" valign="top" rowspan="1" colspan="1">2.79&#x02009;&#x000b1;&#x02009;4.53<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0070" align="left" valign="top" rowspan="1" colspan="1">5.07&#x02009;&#x000b1;&#x02009;5.53</td><td id="dom12435-ent-0071" align="left" valign="top" rowspan="1" colspan="1">4.01&#x02009;&#x000b1;&#x02009;5.14<xref ref-type="fn" rid="dom12435-note-1004">
<sup>&#x02020;</sup>
</xref>
</td><td id="dom12435-ent-0072" align="left" valign="top" rowspan="1" colspan="1">0.204</td></tr><tr><td id="dom12435-ent-0073" align="left" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/l</td><td id="dom12435-ent-0074" align="left" valign="top" rowspan="1" colspan="1">1.28&#x02009;&#x000b1;&#x02009;0.31</td><td id="dom12435-ent-0075" align="left" valign="top" rowspan="1" colspan="1">1.40&#x02009;&#x000b1;&#x02009;0.35<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0076" align="left" valign="top" rowspan="1" colspan="1">1.27&#x02009;&#x000b1;&#x02009;0.30</td><td id="dom12435-ent-0077" align="left" valign="top" rowspan="1" colspan="1">1.42&#x02009;&#x000b1;&#x02009;0.32<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0078" align="left" valign="top" rowspan="1" colspan="1">0.260</td></tr><tr><td id="dom12435-ent-0079" align="left" valign="top" rowspan="1" colspan="1">Free fatty acid, mmol/l</td><td id="dom12435-ent-0080" align="left" valign="top" rowspan="1" colspan="1">0.68&#x02009;&#x000b1;&#x02009;0.27</td><td id="dom12435-ent-0081" align="left" valign="top" rowspan="1" colspan="1">0.58&#x02009;&#x000b1;&#x02009;0.25<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0082" align="left" valign="top" rowspan="1" colspan="1">0.66&#x02009;&#x000b1;&#x02009;0.26</td><td id="dom12435-ent-0083" align="left" valign="top" rowspan="1" colspan="1">0.57&#x02009;&#x000b1;&#x02009;0.27<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0084" align="left" valign="top" rowspan="1" colspan="1">0.977</td></tr><tr><td id="dom12435-ent-0085" align="left" valign="top" rowspan="1" colspan="1">Apo&#x02010;B, g/l</td><td id="dom12435-ent-0086" align="left" valign="top" rowspan="1" colspan="1">0.72&#x02009;&#x000b1;&#x02009;0.21</td><td id="dom12435-ent-0087" align="left" valign="top" rowspan="1" colspan="1">0.79&#x02009;&#x000b1;&#x02009;0.26<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0088" align="left" valign="top" rowspan="1" colspan="1">0.76&#x02009;&#x000b1;&#x02009;0.23</td><td id="dom12435-ent-0089" align="left" valign="top" rowspan="1" colspan="1">0.84&#x02009;&#x000b1;&#x02009;0.28<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0090" align="left" valign="top" rowspan="1" colspan="1">0.628</td></tr><tr><td id="dom12435-ent-0091" align="left" valign="top" rowspan="1" colspan="1">Apo&#x02010;A1, g/l</td><td id="dom12435-ent-0092" align="left" valign="top" rowspan="1" colspan="1">1.51&#x02009;&#x000b1;&#x02009;0.27</td><td id="dom12435-ent-0093" align="left" valign="top" rowspan="1" colspan="1">1.49&#x02009;&#x000b1;&#x02009;0.27</td><td id="dom12435-ent-0094" align="left" valign="top" rowspan="1" colspan="1">1.48&#x02009;&#x000b1;&#x02009;0.22</td><td id="dom12435-ent-0095" align="left" valign="top" rowspan="1" colspan="1">1.48&#x02009;&#x000b1;&#x02009;0.21</td><td id="dom12435-ent-0096" align="left" valign="top" rowspan="1" colspan="1">0.688</td></tr><tr><td id="dom12435-ent-0097" align="left" valign="top" rowspan="1" colspan="1">Adiponectin, ng/dl</td><td id="dom12435-ent-0098" align="left" valign="top" rowspan="1" colspan="1">5824.54&#x02009;&#x000b1;&#x02009;3054.51</td><td id="dom12435-ent-0099" align="left" valign="top" rowspan="1" colspan="1">13&#x02009;321.71&#x02009;&#x000b1;&#x02009;7856.63<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0100" align="left" valign="top" rowspan="1" colspan="1">6137.73&#x02009;&#x000b1;&#x02009;2863.21</td><td id="dom12435-ent-0101" align="left" valign="top" rowspan="1" colspan="1">14&#x02009;253.96&#x02009;&#x000b1;&#x02009;9260.51<xref ref-type="fn" rid="dom12435-note-3004">
<sup>&#x000a7;</sup>
</xref>
</td><td id="dom12435-ent-0102" align="left" valign="top" rowspan="1" colspan="1">0.817</td></tr></tbody></table><table-wrap-foot><fn id="dom12435-note-0002"><p>
<styled-content style="fixed-case">Apo&#x02010;A1</styled-content>, apolipoprotein A1; <styled-content style="fixed-case">Apo&#x02010;B</styled-content>, apolipoprotein B; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">HOMA&#x02010;&#x003b2;</styled-content>, homeostasis model assessment of &#x003b2;&#x02010;cell function; <styled-content style="fixed-case">HOMA&#x02010;IR</styled-content>, homeostasis model assessment of insulin resistance.</p></fn><fn id="dom12435-note-0003"><p>Data are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation.</p></fn><fn id="dom12435-note-0004"><p>Significant changes from baseline to week&#x02009;24 are indicated as follows:</p></fn><fn id="dom12435-note-1004"><label><sup>&#x02020;</sup></label><p>p&#x02009;&#x0003c;&#x02009;0.05;</p></fn><fn id="dom12435-note-2004"><label><sup>&#x02021;</sup></label><p>p&#x0003e;&#x02009;&#x0003c;&#x02009;0.01;</p></fn><fn id="dom12435-note-3004"><label><sup>&#x000a7;</sup></label><p>p&#x02009;&#x0003c;&#x02009;0.001 as determined by a paired <styled-content style="italic-in-any-context">t</styled-content>&#x02010;test.</p></fn><fn id="dom12435-note-0005"><label>*</label><p>p values are for analysis of covariance, after adjusting for baseline values. The <styled-content style="fixed-case">B</styled-content>onferroni method was applied when multiple comparisons were made.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12435-sec-0006"><title>Safety</title><p id="dom12435-para-0009">Among the safety population set (n&#x02009;=&#x02009;253), 130 (51.4%) patients experienced one or more adverse events (AEs; lobeglitazone group, n&#x02009;=&#x02009;66; pioglitazone group, n&#x02009;=&#x02009;64). Severe AEs were reported in 13 patients (5.1%); all of these AEs were considered to be unrelated to the study drug by the investigator. Drug&#x02010;related AEs were reported in 14 patients (5.5%). No differences were observed between the two groups regarding the incidence of AEs, severe AEs, or drug&#x02010;related AEs (Table S3, File S1). Details of the safety variables and the results of the extension study are available in File S1.</p></sec></sec><sec id="dom12435-sec-0007"><title>Discussion</title><p id="dom12435-para-0010">In the present study, lobeglitazone (0.5&#x02009;mg/day) was not inferior to pioglitazone (15&#x02009;mg/day) as an add&#x02010;on therapy to metformin in terms of the reduction in HbA1c concentration after 24&#x02009;weeks. Changes in glycometabolic and lipid variables, and the overall safety profiles in the lobeglitazone group were similar to those observed in the pioglitazone group.</p><p id="dom12435-para-0011">In the present study, lobeglitazone shared some safety issues with pioglitazone, such as oedema and increased body weight; however, it is reassuring that lobeglitazone, a pure PPAR&#x02010;&#x003b3; agonist rather than a dual PPAR agonist, did not show any significant difference in its effects on lipid variables when compared with pioglitazone. Moreover, no severe, drug&#x02010;related AEs (including heart failure requiring admission) were observed during the study period or in the additional 28&#x02010;week extension study.</p><p id="dom12435-para-0012">A clinically important limitation of the present study was that the dose of pioglitazone was only 15&#x02009;mg/day, the highest dose covered by the Korea national health insurance system during the study period. Although up to 30&#x02009;mg/day of pioglitazone is approved for clinical use in Korea and is allowed for patients who have a poor response with a dose of 15&#x02009;mg/day, the use of higher dose incurs an additional cost for patients (without insurance reimbursement). For this reason, the efficacy and safety of higher doses of lobeglitazone and pioglitazone could not be compared in this study. Because lobeglitazone has been shown to be well tolerated in doses of up to 4&#x02009;mg for 7&#x02009;days in a short&#x02010;term study conducted in healthy volunteers <xref rid="dom12435-bib-0009" ref-type="ref">9</xref>, the results of the present study should encourage future international studies comparing the efficacy and safety of higher doses of lobeglitazone and maximum dose of pioglitazone.</p><p id="dom12435-para-0013">In conclusion, the efficacy of lobeglitazone (0.5&#x02009;mg/day) was not inferior to pioglitazone (15&#x02009;mg/day) as an add&#x02010;on to metformin in terms of the change in HbA1c concentration from baseline. Additionally, the effects on lipid variables, adiponectin secretion and AEs were similar to those observed with pioglitazone.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12435-supitem-0001"><caption><p>
<bold>File S1.</bold> Supplementary Methods and Results, Acknowledgments.</p></caption><media xlink:href="DOM-17-599-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0002"><caption><p>
<bold>Table S1.</bold> Patient demographics and baseline characteristics.</p></caption><media xlink:href="DOM-17-599-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0003"><caption><p>
<bold>Table S2.</bold> Demographics and baseline characteristics of patients in extension study.</p></caption><media xlink:href="DOM-17-599-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0004"><caption><p>
<bold>Table S3.</bold> Safety profiles in the safety population over the 24&#x02010;week study period.</p></caption><media xlink:href="DOM-17-599-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0005"><caption><p>
<bold>Table S4.</bold> Adverse events additionally reported during the extension period (Week 25 to 52).</p></caption><media xlink:href="DOM-17-599-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0006"><caption><p>
<bold>Figure S1.</bold> Patient dispositions.</p></caption><media xlink:href="DOM-17-599-s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12435-supitem-0007"><caption><p>
<bold>Figure S2.</bold> Mean changes in fasting plasma glucose (FPG) levels from baseline.</p></caption><media xlink:href="DOM-17-599-s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12435-sec-0008"><title>Acknowledgements</title><p id="dom12435-para-0014">This study was supported by the Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea. Other funding sources and the full list of investigators are available in File S1.</p></ack><ref-list content-type="cited-references" id="dom12435-bibl-0001"><title>References</title><ref id="dom12435-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12435-cit-0001">
<string-name>
<surname>Lewis</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Ferrara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>T</given-names>
</string-name> et al. <article-title>Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study</article-title>. <source>Diabetes Care</source>
<year>2011</year>; <volume>34</volume>: <fpage>916</fpage>&#x02013;<lpage>922</lpage>.<pub-id pub-id-type="pmid">21447663</pub-id></mixed-citation></ref><ref id="dom12435-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12435-cit-0002">
<string-name>
<surname>Home</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Pocock</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Beck&#x02010;Nielsen</surname>
<given-names>H</given-names>
</string-name> et al. <article-title>Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open&#x02010;label trial</article-title>. <source>Lancet</source>
<year>2009</year>; <volume>373</volume>: <fpage>2125</fpage>&#x02013;<lpage>2135</lpage>.<pub-id pub-id-type="pmid">19501900</pub-id></mixed-citation></ref><ref id="dom12435-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12435-cit-0003">
<string-name>
<surname>Nissen</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Wolski</surname>
<given-names>K</given-names>
</string-name>. <article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title>. <source>N Engl J Med</source>
<year>2007</year>; <volume>356</volume>: <fpage>2457</fpage>&#x02013;<lpage>2471</lpage>.<pub-id pub-id-type="pmid">17517853</pub-id></mixed-citation></ref><ref id="dom12435-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12435-cit-0004">
<string-name>
<surname>Corzo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>PR</given-names>
</string-name>. <article-title>Targeting the peroxisome proliferator&#x02010;activated receptor&#x02010;gamma to counter the inflammatory milieu in obesity</article-title>. <source>Diabetes Metab J</source>
<year>2013</year>; <volume>37</volume>: <fpage>395</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">24404510</pub-id></mixed-citation></ref><ref id="dom12435-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12435-cit-0005">
<string-name>
<surname>Colca</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Tanis</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Kletzien</surname>
<given-names>RF</given-names>
</string-name>. <article-title>Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases</article-title>. <source>Expert Opin Investig Drugs</source>
<year>2014</year>; <volume>23</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="dom12435-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12435-cit-0006">
<string-name>
<surname>Kim</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>JT</given-names>
</string-name> et al. <article-title>Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24&#x02010;weeks: a multicenter, randomized, double&#x02010;blind, parallel&#x02010;group, placebo controlled trial</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e92843</fpage>.<pub-id pub-id-type="pmid">24736628</pub-id></mixed-citation></ref><ref id="dom12435-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12435-cit-0007">
<string-name>
<surname>Kim</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HW</given-names>
</string-name> et al. <article-title>Synthesis and biological activity of novel substituted pyridines and purines containing 2,4&#x02010;thiazolidinedione</article-title>. <source>Eur J Med Chem</source>
<year>2004</year>; <volume>39</volume>: <fpage>433</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">15110969</pub-id></mixed-citation></ref><ref id="dom12435-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12435-cit-0008">
<string-name>
<surname>Lee</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>JB</given-names>
</string-name> et al. <article-title>Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione</article-title>. <source>Eur J Med Chem</source>
<year>2005</year>; <volume>40</volume>: <fpage>862</fpage>&#x02013;<lpage>874</lpage>.<pub-id pub-id-type="pmid">15908051</pub-id></mixed-citation></ref><ref id="dom12435-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12435-cit-0009">
<string-name>
<surname>Kim</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>S</given-names>
</string-name> et al. <article-title>Tolerability and pharmacokinetics of lobeglitazone (CKD&#x02010;501), a peroxisome proliferator&#x02010;activated receptor&#x02010;gamma agonist: a single&#x02010; and multiple&#x02010;dose, double&#x02010;blind, randomized control study in healthy male Korean subjects</article-title>. <source>Clin Ther</source>
<year>2011</year>; <volume>33</volume>: <fpage>1819</fpage>&#x02013;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">22047812</pub-id></mixed-citation></ref><ref id="dom12435-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12435-cit-0010">
<string-name>
<surname>Moon</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name> et al. <article-title>CKD&#x02010;501, a novel selective PPARgamma agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks</article-title>. <source>J Appl Toxicol</source>
<year>2014</year>; <volume>34</volume>: <fpage>1271</fpage>&#x02013;<lpage>1284</lpage>.<pub-id pub-id-type="pmid">24026970</pub-id></mixed-citation></ref><ref id="dom12435-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12435-cit-0011">
<string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JE</given-names>
</string-name> et al. <article-title>Carcinogenicity study of CKD&#x02010;501, a novel dual peroxisome proliferator&#x02010;activated receptors alpha and gamma agonist, following oral administration to Sprague Dawley rats for 94&#x02013;101weeks</article-title>. <source>Regul Toxicol Pharmacol</source>
<year>2014</year>; <volume>69</volume>: <fpage>207</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">24747398</pub-id></mixed-citation></ref><ref id="dom12435-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12435-cit-0012">
<string-name>
<surname>Shin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>SH</given-names>
</string-name> et al. <article-title>Assessment of the pharmacokinetics of co&#x02010;administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects</article-title>. <source>Curr Med Res Opin</source>
<year>2012</year>; <volume>28</volume>: <fpage>1213</fpage>&#x02013;<lpage>1220</lpage>.<pub-id pub-id-type="pmid">22697273</pub-id></mixed-citation></ref></ref-list></back></article>